Lewis-Y antigen

Data highlights preclinical efficacy and safety of GNX1021, a novel glycan-targeting ADC, in gastric cancer models NEW TAIPEI CITY, Taiwan, March 27, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that preclinical data on GNX1021 will be presented on April 28 at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. GNX1021 is an antibody-drug conjugate (ADC) targeting branched Lewis B/Y (bLeB/Y), a unique tumor-associated glycan antigen overexpressed in gastric cancer and other solid tumors. The poster will highlight in vivo efficacy and safety findings from gastric cancer models that demonstrate GNX1021's tumor control activity. "We are very pleased that research involving GNX1021, our glycan-targeting ADC, was accepted for presentation at AACR 2025," said Dr. Mei-Chun Yang, CEO of GlycoNex. "AACR is one of the most influential oncology meetings in the world, and the opportunity to showcase the potential of GNX1021 to treat gastric cancer, an often-deadly cancer with few available therapies, highlights the importance of this program." Presentation Details: About GlycoNex Inc. GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects. GlycoNex possesses a robust pipeline led by GNX102, a humanized monoclonal antibody (mAb) designed to target abnormal sugar molecules in cancer cells. GNX102 has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy. GlycoNex is also advancing a portfolio of antibody-drug conjugates (ADCs) that precisely attack cancer cells while sparing healthy tissue. GlycoNex is headquartered in New Taipei City, Taiwan. For more information, visit . Contact s for GlycoNex, Inc. Investor Relations Tiberend Strategic Advisors, Inc. David Irish [email protected] Media Relations Eric Reiss [email protected] SOURCE GlycoNex, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Crossbow Therapeutics will use the funds to develop therapies to treat cancer. Credit: crystal light via Shutterstock.com. Crossbow Therapeutics has raised Series A funds worth $80m to develop a new class of antibody treatments for cancer. MPM BioImpact and Pfizer Ventures led the funding round, with Polaris Partners, BVF Partners and Eli Lilly and Company among others taking part. Recommended Reports Reports LOA and PTSR Model - Vaccine For Oncology in Colorectal Cancer GlobalData Reports LOA and PTSR Model - Gene Therapy To Target Lewis Y Antigen For Lung Cancer in Lung Cancer GlobalData View all Companies Intelligence Eli Lilly and Co Polaris Partners LLC BVF Partners LP Crossbow Corp Pfizer Ventures LLC View all Proceeds will be used to progress the development of new therapies that act on peptide-loaded major histocompatibility complexes (pMHCs) present on cancer cells. To target pMHCs, these therapies will leverage antibodies that imitate T-cell receptors (TCR-mimetics). The company will identify, validate and select the most promising cancer-specific targets, then create TCR-mimetic antibodies that have greater levels of cancer cell affinity and specificity. Such TCR-mimetics will be merged with off-the-shelf T-cell engagers and immunotherapies to create tumour-bolt (T-Bolt) molecules. These T-Bolts can be tailored to treat a variety of cancers. Crossbow Therapeutics CEO Briggs Morrison stated: “With unparalleled accuracy and potency, our revolutionary T-Bolt products strike cancer cells like a crossbow shoots bolts at its target. “The influx of additional capital enables us to scale our efforts to build an arsenal of TCR-mimetic-based immunotherapies designed to overcome the limitations of current treatments.”